News & Events

Press Releases

Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference

October 2, 2019 at 7:30 AM EDT

CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at the upcoming Chardan Annual Genetic Medicines Conference at 8:30 a.m. ET on October 8th in New York, NY.

A live audio webcast of the Chardan presentation will be available on the Events page of the Investors section of the Company website. A replay of the Chardan presentation will also be archived for approximately 30 days on the Events & Presentations page.

About Solid Biosciences

Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.

Investor Contact:
 Carlo Tanzi, Ph.D.
Kendall Investor Relations
617-337-4680
 investors@solidbio.com

Media Contact:
Lindsay Deefholts
ScientPR
416-301-7966
media@solidbio.com

SolidBioLogoDigitalRGB.png

Source: Solid Biosciences Inc.